Cost Effectiveness of Cetuximab Concurrent with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Taiwan
Background: Concomitant chemotherapy with radiotherapy is considered to be the standard of care for patients with head and neck cancer and good performance status. However, published reports on the cost effectiveness of this therapeutic approach are extremely rare.
Objective: The aim of this study was to estimate the cost effectiveness of cetuximab combined with radiotherapy compared with radiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck.
Methods: A decision-tree analysis was used to compare cetuximab combined with radiotherapy and radiotherapy alone in the treatment of patients with locally advanced squamous cell carcinoma of the head and neck from the perspective of the national health payer (the Bureau of National Health Insurance [BNHI]) in Taiwan. The model was based on individual patient data extracted from an international phase III trial. The direct medical costs of care were estimated by clinical expert panels based on the reimbursement price of the BNHI (2007 values). One-way sensitivity analyses were performed while varying the costs and clinical parameters.
Results: The incremental cost per quality-adjusted life-year (QALY) for patients receiving radiotherapy in combination with cetuximab compared with radiotherapy alone was $US36992/QALY in the base-case analysis (2007 values). The sensitivity analysis showed the highest net benefit for radiotherapy alone if the cost of cetuximab increased by 50%.
Conclusion: This study demonstrated that the addition of cetuximab to high-dose radiotherapy regimens is likely to be cost effective in Taiwan because the incremental cost per QALY is below the commonly accepted cost-effectiveness threshold.
- 1.National Institute for Health and Clinical Excellence (NICE). Guideline on cancer services: improving outcomes in the head and neck cancers: the manual. London: NICE, 2007Google Scholar
- 5.Taiwan Cancer Registry [online]. Available from URL: http://tcr.cph.ntu.edu.tw/main.php?Page=A5B3#t01 [Accessed 2010 2 Jan]
- 6.Priebe SL, Aleksejuniene J, Dharamsi S. Oral cancer and cultural factors in Asia. Can J Dent Hygiene 2008; 42(6): 291–5Google Scholar
- 13.Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161–71PubMedCrossRefGoogle Scholar
- 24.Lu T, Zhao C, Chen C, et al. An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): preliminary report [abstract no. 5577]. J Clin Oncol 2010; 28: 15sGoogle Scholar
- 27.Fee-charging standards for requestingdata from the Bureau of National Health Insurance, Department of Health, Executive Yuan [online]. Available from URL: http://dohlaw.doh.gov.tw/Chi/EngContent.asp?msgid=263&KeyWord= [Accessed 2011 Apr 8]
- 36.WHO Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2001Google Scholar
- 37.NCCN head and neck cancer guidelines. Clinical practice guidelines in oncology (version 1.2007) [online]. Available from URL: http://www.nccn.org [Accessed 2010 Apr 15]
- 39.ClinicalTrialsFeeds.org. Cetuximab plus radiotherapy versus cisplatin plus radiotherapy in locally advanced head and neck cancer [online]. Available from URL: http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01216020 [Accessed 2011 Apr 17]